Finding accredited CPD
This Educational Review discusses the role of intravenous immunoglobulins (IVIg) in treating patients with myasthenia gravis. IVIg is a well-established therapy with a relatively fast onset of action and a first-line treatment option for patients in myasthenic crisis. IVIg is also indicated prior to surgery and/or thymectomy in generalised disease, and as maintenance treatment in moderate to severe MG where other treatments have been ineffective or intolerable.
This activity is accepted by CPD Home as Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide.
Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.
*Medical Board of Australia’s (MBA)’s Registration Standard: Continuing professional development (the Standard)
